The entry of [D-penicillamine2,5]enkephalin into the central nervous system: Saturation kinetics and specificity

Sarah A. Thomas, Thomas J. Abbruscato, Victor J Hruby, Thomas P Davis

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The delta opioid receptor-selective, enzymatically stable peptide [D- Penicillamine2,5]enkephalin (DPDPE) has recently acquired special significance with the identification of a saturable uptake system for this analgesic into the CNS. The aim of the present study was to characterize further the entry of [3H]DP-DPE into the brain and CSF by means of a bilateral in situ brain perfusion method. Initial experiments revealed a saturable [3H]DPDPE uptake into the brain that followed Michaelis-Menten type kinetics with a K(m) value of 45.5 ± 27.6 μM, a V(max) value of 51.1 ± 13.2 pmol · min · g-1 and a K(d) value of 0.6± 0.3 μl · min-1 · g-1. Uptake of [3H]DPDPE into the CSF could not be inhibited (K(d) = 0.9 ± 0.1 μl · min-1 · g-1). Entry of [3H]DPDPE into the CNS was not inhibited in the presence of 10 mM 2-aminobicyclo-[2,2,1]-heptane-2- carboxylic acid (BCH) or 50 μM ICI 174,864, which suggests that the saturable mechanism does not involve the large neutral amino acid transporter or binding to opioid receptors. It would also appear that [3H]D-PDPE is not in competition with either poly-L-lysine or insulin to enter the CNS. However, both of these substances significantly increased the CNS entry of [3H]DPDPE but not that of the vascular space marker [14C]sucrose, and this may have valuable clinical implications. It is not known at present which saturable uptake mechanism is responsible for the CNS entry of [3H]DPDPE, but overall the results suggest a carrier-mediated transport system.

Original languageEnglish (US)
Pages (from-to)1235-1240
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume280
Issue number3
StatePublished - Mar 1997

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Enkephalins
Central Nervous System
Amino Acid Transport System L
Brain
delta Opioid Receptor
Opioid Receptors
Lysine
Blood Vessels
Analgesics
Sucrose
Perfusion
Insulin
Peptides

ASJC Scopus subject areas

  • Pharmacology

Cite this

The entry of [D-penicillamine2,5]enkephalin into the central nervous system : Saturation kinetics and specificity. / Thomas, Sarah A.; Abbruscato, Thomas J.; Hruby, Victor J; Davis, Thomas P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 3, 03.1997, p. 1235-1240.

Research output: Contribution to journalArticle

@article{667923f13b0a4f6184164fd15f3219a8,
title = "The entry of [D-penicillamine2,5]enkephalin into the central nervous system: Saturation kinetics and specificity",
abstract = "The delta opioid receptor-selective, enzymatically stable peptide [D- Penicillamine2,5]enkephalin (DPDPE) has recently acquired special significance with the identification of a saturable uptake system for this analgesic into the CNS. The aim of the present study was to characterize further the entry of [3H]DP-DPE into the brain and CSF by means of a bilateral in situ brain perfusion method. Initial experiments revealed a saturable [3H]DPDPE uptake into the brain that followed Michaelis-Menten type kinetics with a K(m) value of 45.5 ± 27.6 μM, a V(max) value of 51.1 ± 13.2 pmol · min · g-1 and a K(d) value of 0.6± 0.3 μl · min-1 · g-1. Uptake of [3H]DPDPE into the CSF could not be inhibited (K(d) = 0.9 ± 0.1 μl · min-1 · g-1). Entry of [3H]DPDPE into the CNS was not inhibited in the presence of 10 mM 2-aminobicyclo-[2,2,1]-heptane-2- carboxylic acid (BCH) or 50 μM ICI 174,864, which suggests that the saturable mechanism does not involve the large neutral amino acid transporter or binding to opioid receptors. It would also appear that [3H]D-PDPE is not in competition with either poly-L-lysine or insulin to enter the CNS. However, both of these substances significantly increased the CNS entry of [3H]DPDPE but not that of the vascular space marker [14C]sucrose, and this may have valuable clinical implications. It is not known at present which saturable uptake mechanism is responsible for the CNS entry of [3H]DPDPE, but overall the results suggest a carrier-mediated transport system.",
author = "Thomas, {Sarah A.} and Abbruscato, {Thomas J.} and Hruby, {Victor J} and Davis, {Thomas P}",
year = "1997",
month = "3",
language = "English (US)",
volume = "280",
pages = "1235--1240",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - The entry of [D-penicillamine2,5]enkephalin into the central nervous system

T2 - Saturation kinetics and specificity

AU - Thomas, Sarah A.

AU - Abbruscato, Thomas J.

AU - Hruby, Victor J

AU - Davis, Thomas P

PY - 1997/3

Y1 - 1997/3

N2 - The delta opioid receptor-selective, enzymatically stable peptide [D- Penicillamine2,5]enkephalin (DPDPE) has recently acquired special significance with the identification of a saturable uptake system for this analgesic into the CNS. The aim of the present study was to characterize further the entry of [3H]DP-DPE into the brain and CSF by means of a bilateral in situ brain perfusion method. Initial experiments revealed a saturable [3H]DPDPE uptake into the brain that followed Michaelis-Menten type kinetics with a K(m) value of 45.5 ± 27.6 μM, a V(max) value of 51.1 ± 13.2 pmol · min · g-1 and a K(d) value of 0.6± 0.3 μl · min-1 · g-1. Uptake of [3H]DPDPE into the CSF could not be inhibited (K(d) = 0.9 ± 0.1 μl · min-1 · g-1). Entry of [3H]DPDPE into the CNS was not inhibited in the presence of 10 mM 2-aminobicyclo-[2,2,1]-heptane-2- carboxylic acid (BCH) or 50 μM ICI 174,864, which suggests that the saturable mechanism does not involve the large neutral amino acid transporter or binding to opioid receptors. It would also appear that [3H]D-PDPE is not in competition with either poly-L-lysine or insulin to enter the CNS. However, both of these substances significantly increased the CNS entry of [3H]DPDPE but not that of the vascular space marker [14C]sucrose, and this may have valuable clinical implications. It is not known at present which saturable uptake mechanism is responsible for the CNS entry of [3H]DPDPE, but overall the results suggest a carrier-mediated transport system.

AB - The delta opioid receptor-selective, enzymatically stable peptide [D- Penicillamine2,5]enkephalin (DPDPE) has recently acquired special significance with the identification of a saturable uptake system for this analgesic into the CNS. The aim of the present study was to characterize further the entry of [3H]DP-DPE into the brain and CSF by means of a bilateral in situ brain perfusion method. Initial experiments revealed a saturable [3H]DPDPE uptake into the brain that followed Michaelis-Menten type kinetics with a K(m) value of 45.5 ± 27.6 μM, a V(max) value of 51.1 ± 13.2 pmol · min · g-1 and a K(d) value of 0.6± 0.3 μl · min-1 · g-1. Uptake of [3H]DPDPE into the CSF could not be inhibited (K(d) = 0.9 ± 0.1 μl · min-1 · g-1). Entry of [3H]DPDPE into the CNS was not inhibited in the presence of 10 mM 2-aminobicyclo-[2,2,1]-heptane-2- carboxylic acid (BCH) or 50 μM ICI 174,864, which suggests that the saturable mechanism does not involve the large neutral amino acid transporter or binding to opioid receptors. It would also appear that [3H]D-PDPE is not in competition with either poly-L-lysine or insulin to enter the CNS. However, both of these substances significantly increased the CNS entry of [3H]DPDPE but not that of the vascular space marker [14C]sucrose, and this may have valuable clinical implications. It is not known at present which saturable uptake mechanism is responsible for the CNS entry of [3H]DPDPE, but overall the results suggest a carrier-mediated transport system.

UR - http://www.scopus.com/inward/record.url?scp=0030615087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030615087&partnerID=8YFLogxK

M3 - Article

C2 - 9067309

AN - SCOPUS:0030615087

VL - 280

SP - 1235

EP - 1240

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -